Patients with open-angle glaucoma (OAG) had a significant reduction in IOP and did not require anti-glaucoma medications over 1 year postoperatively when micro-invasive glaucoma surgery (MIGS) was performed, according to interim results for a MIGS study group that were reported by David F. Chang, MD.
Patients with sleep apnea are more likely to develop glaucoma compared with those without the sleep condition, according to a new study.
The University of California, Los Angeles’ (UCLA) Jules Stein Eye Institute announced it has begun pursuing a long-term affiliation with the Doheny Eye Institute.
Bausch + Lomb and TheraPearl LLC have announced the creation of the Bausch + Lomb THERA°PEARL Eye Mask, a product aimed at those suffering from a variety of common ailments, including the most common type of dry eye.
InnFocus Inc. has received authorization from the FDA to begin the phase I trial of the InnFocus MicroShunt to treat open-angle glaucoma (OAG).
Ophthalmologists are nearing a crossroads with the replacement of phacoemulsification by femtosecond laser technology. New femtosecond laser technology is costly, and surgeons must decide if this technology is right for their practices, explained John Vukich, MD.
Optovue Inc. has received FDA 510 (k) clearance for its new iFusion combination system and has begun filing customer orders worldwide.
Alcon Research Ltd. has accused Mylan Inc. of seeking government approval for a drug that would infringe three of its patents for a glaucoma treatment.
Omeros Corp. has announced that it recently submitted a new drug application to the FDA for approval of a new drug for use in patients undergoing IOL replacement (ILR) surgery.
Practicing reverse motivation may be just what the doctor ordered when it comes to helping staff members achieve their goals, relates columnist Dianna Graves.
Cataract surgeons wanting to tap into the premium IOL market might consider implanting toric IOLs.
Toric IOL implantation provides a reliably effective method for reducing existing astigmatism in patients undergoing cataract surgery, but careful marking of the eye to guide accurate axis alignment of the IOL is essential for achieving good outcomes, said Bonnie An Henderson, MD.
A new +2.5 D add version of a multifocal IOL features a re-designed optic that enhances visual function at intermediate and distance and delivers excellent visual quality.
As consumer interest in alternative therapies grows and considering the potential for harm, ophthalmologists need to be prepared to speak about this topic with their patients.
Ophthalmology Times introduces this new series called “Gloves Off with Gulani” that is part of the full-spectrum concept of a “super-specialty,” in which Arun C. Gulani, MD, will present prototype case studies and accept input to show how every case-no matter how difficult-deserves a mindset of emmetropia. Look for the first “gloves-off” encounter-“Multifocal IOL nightmare: Reversed to 20/20”-in the Oct. 1 issue of Ophthalmology Times.
A light-adjustable IOL continues to show potential for delivering customized vision with predictable results.
While manual limbal relaxing incisions and femtosecond femtosecond astigmatic keratotomies can address mild to moderate astigmatism, toric IOLs are quite effective at all ranges of astigmatism, relates one surgeon.
Where the experts may have gotten this one wrong
A single-piece hydrophobic acrylic IOL has many features that make it a good choice for a monofocal implant in routine and challenging cataract surgery cases.
What the $400 million deal brings to the laser cataract surgery market
Topcon Medical Laser Systems has received FDA 510(k) clearance for its portable, dual-port, pattern-scanning laser (PASCAL Synthesis).
The Transparency Commission of the French National Authority for Health has issued a favorable opinion for the reimbursement and hospital listing of Alimera Sciences’ fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of chronic diabetic macular edema.
Ophthalmologists and other physicians are finding it more challenging to stay on top of all the clinical research and information that is presented before them. However, digital devices may provide an answer to help physicians absorb all this information.
Essilor International will acquire PPG Industries’ 51% stake in Transitions Optical, announced the companies in prepared statements. Essilor has held a 49% share of Transitions Optical since the joint-venture formation 23 years ago.
As dry eye syndrome (DES) affects more and more patients over the next 10 years, pharmaceutical companies are expecting to expand their clinical products globally to treat the condition, thus tripling the market’s global revenue over the next decade.
Allergan Inc. has named Douglas S. Ingram as the company’s new president. Ingram will lead the company’s global commercial operations, with responsibility for its broad portfolio of pharmaceutical, consumer, and medical device products.
Deep sclerectomy augmented with implantation of a gold mini-shunt (Gold Mini Shunt Plus, SOLX) in the suprachoroidal space is a safe and effective technique for lowering IOP in eyes with moderate to advanced open-angle glaucoma, according to findings from researchers at the University of Montreal.
Bausch + Lomb (B + L) has acquired an option to license an investigational compound currently in phase II development for the treatment of dry eye syndrome. The compound, called MIM-D3 and developed by Mimetogen Pharmaceuticals Inc., has the potential to be the first in a new class of agents called TrkA agonists, said the companies in a joint statement.
The European Commission has granted Novartis Pharmaceuticals a new indication for ranibizumab (Lucentis) to treat patients with choroidal neovascularization (CNV) secondary to pathologic myopia.
U.S. News & World Report has released its annual Best Hospitals rankings for 2013-2014. Rounding out the top three ophthalmology hospitals in the United States are: Bascom Palmer Eye Institute; Wills Eye Hospital; and Wilmer Eye Institute.
